Multiple sclerosis Study Guide

📖 Core Concepts Multiple Sclerosis (MS) – an autoimmune, demyelinating disease of the CNS; immune cells attack myelin sheaths, leading to lesions and neurologic dysfunction. Demyelination – loss of the insulating myelin layer (produced by oligodendrocytes), causing slowed or blocked nerve conduction. Dissemination in Space (DIS) & Time (DIT) – the two MRI/clinical requirements for a definitive MS diagnosis (lesions in ≥2 typical CNS regions and evidence that they occurred at different times). Clinically Isolated Syndrome (CIS) – a first neurologic event suggestive of MS that does not yet meet full criteria. Relapsing‑Remitting MS (RRMS) – attacks (relapses) followed by remission with no new disease activity; 85 % present with this pattern. Secondary Progressive MS (SPMS) – transition from RRMS to gradual worsening without clear relapses. Primary Progressive MS (PPMS) – steady deterioration from onset, no distinct relapses; 10‑20 % of cases. Oligoclonal Bands (OCBs) – IgG bands in CSF present in 75‑85 % of patients; strong supportive diagnostic marker. Key Symptoms – visual loss/eye pain, double vision, Lhermitte’s sign, Uhthoff’s phenomenon, motor weakness, sensory loss, fatigue, bladder/bowel dysfunction, cognitive slowing. 📌 Must Remember Epidemiology: 2.9 M worldwide; prevalence ≈ 36/100 k (higher in northern latitudes, female : male ≈ 3 : 1). Risk Factors: HLA‑DRB115:01 (DR15) allele, EBV infection (≈ 32‑fold risk), low vitamin D, smoking, adolescent obesity, higher latitude. McDonald 2017 Criteria: ≥ 2 clinical attacks or 1 attack + MRI showing ≥ 2 lesions or OCBs; lesions must be in ≥ 2 typical regions (periventricular, optic nerve, brainstem, spinal cord). Acute Relapse Treatment: IV methylprednisolone 1 g/day × 3‑5 days (or oral equivalent) → accelerates recovery. First‑Line DMTs (RRMS): Interferon‑β (≈ 30 % relapse reduction), Glatiramer acetate (≈ 30 % reduction). High‑Efficacy DMTs: Natalizumab, Alemtuzumab, Cladribine, Fingolimod, Ocrelizumab (PPMS‑only approved). PPMS‑Specific: Ocrelizumab is the only FDA‑approved disease‑modifying drug for primary progressive disease. EDSS: 0 = normal, 6.0 = requires walking aid, 8.0 = chair/bed‑bound; higher scores = higher fall risk. Prognostic Clues: Younger onset, female sex, RRMS course, fewer early attacks → better long‑term outcome. 🔄 Key Processes Lesion Formation Blood‑brain barrier (BBB) disruption → T‑cell entry → cytokine release → B‑cell activation → oligoclonal IgG → demyelination → axonal loss. Diagnosis Workflow Clinical suspicion → MRI brain/spine → assess DIS (≥ 2 regions) → assess DIT (simultaneous or sequential lesions, or OCBs) → apply McDonald criteria → confirm MS. Acute Relapse Management Identify relapse → high‑dose IV methylprednisolone (1 g/day × 3‑5 days) → assess response → if refractory → consider plasma exchange. DMT Initiation Decision After first attack + ≥ 2 MRI lesions → start first‑line DMT → monitor disease activity → escalate to high‑efficacy DMT if breakthrough activity. 🔍 Key Comparisons RRMS vs. SPMS – RRMS: discrete relapses + remission; SPMS: gradual worsening with fewer relapses. Interferon‑β vs. Glatiramer Acetate – Both first‑line; interferon‑β → flu‑like symptoms, injection‑site irritation; glatiramer → post‑injection flushing, chest tightness (rare). Natalizumab vs. Ocrelizumab – Natalizumab: α4‑integrin blocker, high relapse reduction, PML risk (1/600). Ocrelizumab: CD20 B‑cell depletor, effective in RRMS & PPMS, lower infection risk profile. IV Methylprednisolone vs. Oral Prednisone – Same efficacy; IV preferred for severe attacks, oral for convenience. ⚠️ Common Misunderstandings “Vaccinations cause MS” – Large studies show no causal link; vaccines are safe. “Vitamin D cures MS” – Supplementation improves risk profile but does not reliably change relapse rate or progression. “All DMTs work equally for progressive forms” – Only ocrelizumab (PPMS) and siponimod/cladribine (SPMS) have proven efficacy; most first‑line agents are for RRMS. “OCBs are always present” – Present in 75‑85 % but a negative CSF does not rule out MS. 🧠 Mental Models / Intuition “Fire‑break” model: Think of the BBB as a firewall. When it fails, immune “flames” (T/B cells) flood in, burning myelin (demyelination). Early attacks are like small sparks—easy to put out with steroids; repeated sparks weaken the firewall, leading to permanent damage (scar‑like plaques). “Space‑Time Puzzle”: MS diagnosis is a two‑piece puzzle – you need space (lesions in different CNS regions) and time (lesions appear at different moments). If either piece is missing, you only have a “possible MS” scenario. 🚩 Exceptions & Edge Cases Red‑flag features → age < 15 or > 60 at onset, rapid progression, atypical cranial nerve involvement → consider alternative diagnoses (e.g., NMO, sarcoidosis). CIS conversion – 30‑70 % of CIS patients develop definite MS; risk rises with multiple MRI lesions. Pregnancy – Symptoms often improve during gestation, but relapse risk spikes in the first 3 months postpartum. 📍 When to Use Which First‑line DMT (interferon‑β or glatiramer) → newly diagnosed RRMS with low disease activity. High‑efficacy DMT (natalizumab, ocrelizumab, alemtuzumab, cladribine, fingolimod) → breakthrough disease on first‑line, high lesion load, or rapidly evolving RRMS. Ocrelizumab → any PPMS patient (or RRMS if high disease activity). Plasma exchange → severe steroid‑refractory relapse (especially optic neuritis or spinal cord attacks). Physical/occupational therapy → all patients for functional maintenance, regardless of disease stage. 👀 Patterns to Recognize Visual symptoms + optic nerve lesion → suspect optic neuritis → early MS indicator. Heat‑related worsening → Uhthoff’s phenomenon → suggests demyelination affecting conduction. Neck flexion‑induced electric shock down the back → Lhermitte’s sign → classic for cervical spinal cord lesions. New gadolinium‑enhancing lesion on MRI → active inflammation → may trigger steroid therapy. 🗂️ Exam Traps “OCBs are diagnostic” – OCBs are supportive but not definitive; must be combined with DIS/DIT. “All DMTs are safe in pregnancy” – Only interferon‑β and glatiramer acetate are considered relatively safe; most others are contraindicated. “PPMS patients never have relapses” – They can have occasional relapses, but the dominant pattern is steady progression. “Higher vitamin D guarantees no MS” – Vitamin D reduces risk but does not prevent disease entirely. “MRI alone can diagnose MS without clinical criteria” – McDonald criteria still require clinical correlation; isolated MRI lesions without symptoms are not sufficient.